Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Harrow Health ( (HROW) ) is now available.
On March 24, 2026, Harrow, Inc. launched a private add-on offering of $50 million in 8.625% senior unsecured notes due 2030, targeting qualified institutional buyers in the U.S. under Rule 144A and non-U.S. investors under Regulation S. The new notes will form a single series with the $250 million of identical 2030 notes issued on September 12, 2025, and will be guaranteed on a senior unsecured basis by certain existing and future restricted subsidiaries.
Harrow plans to use the net proceeds for general corporate purposes, including growth initiatives such as new product launches, product development and strategic business development opportunities, signaling an intention to further scale its ophthalmic portfolio. The transaction, which remains subject to market and other conditions, underscores the company’s reliance on debt markets to fund expansion while highlighting execution and market risks that could prevent completion of the offering on favorable terms or at all.
The most recent analyst rating on (HROW) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.
The score is held back primarily by leveraged financials, ongoing net losses, and historically weak/volatile cash conversion, alongside a bearish technical trend (below major moving averages with negative MACD). These are partially offset by a positive earnings outlook with specific 2026 revenue/adjusted EBITDA guidance and continued product-driven growth expectations.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Harrow, Inc., based in Nashville and listed on Nasdaq as HROW, is a leading North American provider of ophthalmic disease management solutions. The company offers a broad portfolio of medications for conditions affecting both the front and back of the eye, including dry eye disease, neovascular age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface disorders and retina diseases, focusing on safe, accessible and affordable therapies that improve outcomes.
Founded with an emphasis on patient compliance and clinical effectiveness, Harrow has built a market position around comprehensive ophthalmic coverage rather than single-condition products. Its strategy targets both common and complex eye diseases, positioning the firm as a specialist player in the growing eye-care therapeutics market and aligning its product development with long-term demographic and healthcare demand trends.
Average Trading Volume: 748,834
Technical Sentiment Signal: Hold
Current Market Cap: $1.27B
Learn more about HROW stock on TipRanks’ Stock Analysis page.